Exelixis Inc. (NASDAQ:EXEL) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $9.39 and last traded at $9.25, with a volume of 3,392,257 shares traded. The stock had previously closed at $9.18.

A number of brokerages have issued reports on EXEL. Cowen and Company reissued a “buy” rating on shares of Exelixis in a report on Sunday, April 17th. Leerink Swann reissued a “buy” rating and issued a $8.00 price target (up previously from $7.00) on shares of Exelixis in a report on Thursday, May 12th. Finally, Stifel Nicolaus raised their price target on shares of Exelixis from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Tuesday, April 26th. Five analysts have rated the stock with a buy rating, Exelixis has an average rating of “Buy” and a consensus target price of $8.17.

The company’s market capitalization is $2.09 billion. The company has a 50 day moving average of $8.18 and a 200-day moving average of $5.59.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, May 4th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.02. The firm had revenue of $15.40 million for the quarter, compared to analysts’ expectations of $9.11 million. The business’s quarterly revenue was up 63.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.18) earnings per share. Equities analysts predict that Exelixis Inc. will post ($0.97) earnings per share for the current year.

In related news, Director Lance Willsey bought 40,000 shares of the stock in a transaction dated Monday, May 9th. The shares were purchased at an average price of $4.97 per share, with a total value of $198,800.00. Following the completion of the acquisition, the director now owns 548,273 shares of the company’s stock, valued at $2,724,916.81. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

An institutional investor recently raised its position in Exelixis stock. California State Teachers Retirement System increased its stake in Exelixis Inc. (NASDAQ:EXEL) by 1.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 417,800 shares of the biotechnology company’s stock after buying an additional 6,682 shares during the period. California State Teachers Retirement System owned about 0.18% of Exelixis worth $2,356,000 as of its most recent SEC filing.

Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.